GB9721075D0 - Materials and methods relating to the stimulation of cells - Google Patents

Materials and methods relating to the stimulation of cells

Info

Publication number
GB9721075D0
GB9721075D0 GBGB9721075.1A GB9721075A GB9721075D0 GB 9721075 D0 GB9721075 D0 GB 9721075D0 GB 9721075 A GB9721075 A GB 9721075A GB 9721075 D0 GB9721075 D0 GB 9721075D0
Authority
GB
United Kingdom
Prior art keywords
stimulation
cells
materials
methods relating
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9721075.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to GBGB9721075.1A priority Critical patent/GB9721075D0/en
Publication of GB9721075D0 publication Critical patent/GB9721075D0/en
Priority to PCT/GB1998/002978 priority patent/WO1999017801A2/en
Priority to AU92763/98A priority patent/AU9276398A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
GBGB9721075.1A 1997-10-03 1997-10-03 Materials and methods relating to the stimulation of cells Ceased GB9721075D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9721075.1A GB9721075D0 (en) 1997-10-03 1997-10-03 Materials and methods relating to the stimulation of cells
PCT/GB1998/002978 WO1999017801A2 (en) 1997-10-03 1998-10-05 Materials and methods relating to the stimulation of cells
AU92763/98A AU9276398A (en) 1997-10-03 1998-10-05 Materials and methods relating to the stimulation of cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721075.1A GB9721075D0 (en) 1997-10-03 1997-10-03 Materials and methods relating to the stimulation of cells

Publications (1)

Publication Number Publication Date
GB9721075D0 true GB9721075D0 (en) 1997-12-03

Family

ID=10820052

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9721075.1A Ceased GB9721075D0 (en) 1997-10-03 1997-10-03 Materials and methods relating to the stimulation of cells

Country Status (3)

Country Link
AU (1) AU9276398A (en)
GB (1) GB9721075D0 (en)
WO (1) WO1999017801A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6775320B1 (en) 1999-03-12 2004-08-10 Aware, Inc. Method and a multi-carrier transceiver supporting dynamic switching between active application sets
AU784614B2 (en) * 2000-01-24 2006-05-11 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
US7238360B2 (en) 2000-06-30 2007-07-03 Unversity Of Louisville Research Foundation, Inc. Alteration of cell membrane with B7
EP3765093A4 (en) * 2018-03-15 2021-12-08 Fundamental Solutions Corporation Programmable immunocyte receptor complex system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633731A1 (en) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybrid cells used as anti-cancer vaccine

Also Published As

Publication number Publication date
AU9276398A (en) 1999-04-27
WO1999017801A2 (en) 1999-04-15
WO1999017801A3 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
IL134842A0 (en) Method of delivering genes to antigen presenting cells of the skin
PL332741A1 (en) Battery and method of making same
EP1119365A4 (en) Composition and method of using tumor cells
GB9814619D0 (en) Materials and methods relating to encapsulation
GB9814036D0 (en) Materials and methods relating to the induction of apoptosis in target cells
GB9721075D0 (en) Materials and methods relating to the stimulation of cells
HUP9800146A3 (en) Thalidomide-derivatives and use of them
IL140931A0 (en) Methods and materials relating to novel cd39-like polypeptides
GB9620152D0 (en) Improvements in or relating to the manufacture and use of aerated concrete
GB9605515D0 (en) Improvements in or relating to cell stimulation
GB9606415D0 (en) Improvements in and relating to the generation of elecricity
GB9703276D0 (en) Materials and methods relating to the protection of useful immune cells
GB9708089D0 (en) Materials and methods relating to stabilising substances in cells
ZA988803B (en) Novel FT-0554 substance and its production
EP0974648A4 (en) Novel cell line and screening method with the use of the same
GB9701867D0 (en) Materials and methods relating to cell membrane proteins
AU3340399A (en) Use of urocortin and like polypeptides in therapy
GB9708932D0 (en) Improvements in and relating to the manufacture of snack products
GB9700667D0 (en) Materials and methods relating to the treatment of biofilms
GB9701782D0 (en) Improvements relating to covering materials and methods
GB9722214D0 (en) Improvements in and relating to the manufacture of fire surrounds
IL159948A0 (en) Stimulation of hematopoietic cells in vitro
GB9718546D0 (en) Improvements in or Relating to Immobilisation of Cells
GB9626318D0 (en) Improvements in and relating to the production of active fluorine
GB9422005D0 (en) Improvements relating to soil and stone separators

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)